Eric Santoni Rugiu

Eric Santoni Rugiu is a Clinical Professor in the Department of Clinical Medicine at the University of Copenhagen, specializing in pathology and oncology with a focus on thoracic malignancies. His work bridges clinical practice and molecular research to advance targeted cancer therapies.

His primary research interests include:

• Molecular mechanisms of ALK-rearranged and ROS1-positive non-small cell lung cancer
• Resistance pathways in tyrosine kinase inhibitor therapies
• Epidemiology and comorbidities of thymic epithelial tumors
• Driver gene identification in malignant pleural mesothelioma
• Real-world treatment optimization for advanced lung cancer
• Novel combination therapies targeting autophagy and metabolic pathways

Analysis of his 154 research outputs reveals a dominant focus on precision oncology for thoracic cancers, particularly leveraging Danish population cohorts to study ALK-positive NSCLC treatment efficacy. His recent publications emphasize refining first-line therapy selection, overcoming drug resistance through combination strategies, and identifying new therapeutic targets in rare thoracic malignancies.

Dr. Santoni-Rugiu maintains extensive national and international collaborations, with co-author networks spanning multiple European countries and Asia, reflecting his active engagement in global oncology research consortia.